1. Characterization and treatment of chronic active Epstein- Barr virus disease: a 28-year experience in the United States by Jeffrey I. Cohen, Elaine S. Jaffe, Janet K. Dale, Stefania Pittaluga, Helen E. Heslop, Cliona M. Rooney, Stephen Gottschalk, Catherine M. Bollard, V. Koneti Rao, Adriana Marques, Peter D. Burbelo, Siu-Ping Turk, Rachael Fulton, Alan S. Wayne, Richard F. Little, Mitchell S. Cairo, Nader K. El-Mallawany, Daniel Fowler, Claude Sportes, Michael R. Bishop, Wyndham Wilson, and Stephen E. Straus Blood Volume 117(22):5835-5849 June 2, 2011 ©2011 by American Society of Hematology

2. EBV RNA in both CD20+ and CD20− B cells in a lymph node from patient 16. Jeffrey I. Cohen et al. Blood 2011;117:5835-5849 ©2011 by American Society of Hematology

3. EBV disease involving skin, lymph nodes, and spleen. Jeffrey I. Cohen et al. Blood 2011;117:5835-5849 ©2011 by American Society of Hematology

4. Levels of antibody to EBV lytic proteins and EBNA1 by the luciferase immunoprecipitation system assay in EBV-seropositive control patients (CTRL), patients with CAEBV, and EBV- seronegative control patients. Jeffrey I. Cohen et al. Blood 2011;117:5835-5849 ©2011 by American Society of Hematology

5. Cytokine levels in patients with CAEBV. Levels of IL-6, IL-10, TNF-α, and IFN-γ are shown in pg/mL. Jeffrey I. Cohen et al. Blood 2011;117:5835-5849 ©2011 by American Society of Hematology

6. Clinical course. Jeffrey I. Cohen et al. Blood 2011;117:5835-5849 ©2011 by American Society of Hematology